William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating on August 19.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin has given his Buy rating due to a combination of factors surrounding uniQure’s promising developments in their Huntington’s disease treatment, AMT-130. The upcoming release of top-line data from a pivotal Phase I/II trial is a significant milestone, as it will inform the company’s BLA filing anticipated in early 2026.
Corwin’s optimism is rooted in the expectation that the high-dose AMT-130 treatment will significantly slow disease progression, with a potential 50%-65% reduction as measured by the composite Unified Huntington’s Disease Rating Scale. If the trial results meet these expectations, AMT-130 could become the first approved therapy addressing the root cause of Huntington’s disease, positioning uniQure at the forefront of innovative treatments.
In another report released on August 19, Leerink Partners also reiterated a Buy rating on the stock with a $48.00 price target.